-
2
-
-
3943107573
-
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints
-
Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann Rev Biochem 2004, 73:39-85.
-
(2004)
Ann Rev Biochem
, vol.73
, pp. 39-85
-
-
Sancar, A.1
Lindsey-Boltz, L.A.2
Unsal-Kacmaz, K.3
Linn, S.4
-
3
-
-
0034707047
-
The DNA damage response: putting checkpoints in perspective
-
Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
-
(2000)
Nature
, vol.408
, pp. 433-439
-
-
Zhou, B.B.1
Elledge, S.J.2
-
4
-
-
0029808466
-
Cell cycle checkpoints: preventing an identity crisis
-
Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274:1664-1672.
-
(1996)
Science
, vol.274
, pp. 1664-1672
-
-
Elledge, S.J.1
-
5
-
-
33747830026
-
Artificial transmutation of the gene
-
Muller H.J. Artificial transmutation of the gene. Science 1927, 66:84-87.
-
(1927)
Science
, vol.66
, pp. 84-87
-
-
Muller, H.J.1
-
6
-
-
84964160994
-
Effect of sublethal doses of monochromatic ultraviolet radiation on bacteria in liquid suspensions
-
Hollaender A., Curtis J.T. Effect of sublethal doses of monochromatic ultraviolet radiation on bacteria in liquid suspensions. Proc Soc Exp Biol Med 1935, 33:61-62.
-
(1935)
Proc Soc Exp Biol Med
, vol.33
, pp. 61-62
-
-
Hollaender, A.1
Curtis, J.T.2
-
7
-
-
62349099494
-
The effects of sublethal doses of monochromatic ultraviolet radiation on the growth properties of bacteria
-
Hollaender A., Duggar B.M. The effects of sublethal doses of monochromatic ultraviolet radiation on the growth properties of bacteria. J Bacteriol 1938, 36:17-37.
-
(1938)
J Bacteriol
, vol.36
, pp. 17-37
-
-
Hollaender, A.1
Duggar, B.M.2
-
8
-
-
70350504453
-
The DNA-damage response in human biology and disease
-
Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
-
(2009)
Nature
, vol.461
, pp. 1071-1078
-
-
Jackson, S.P.1
Bartek, J.2
-
9
-
-
63749131243
-
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
-
Reinhardt H.C., Yaffe M.B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009, 21:245-255.
-
(2009)
Curr Opin Cell Biol
, vol.21
, pp. 245-255
-
-
Reinhardt, H.C.1
Yaffe, M.B.2
-
10
-
-
58849146288
-
Distinct mechanisms act in concert to mediate cell cycle arrest
-
Toettcher J.E., Loewer A., Ostheimer G.J., et al. Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci USA 2009, 106:785-790.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 785-790
-
-
Toettcher, J.E.1
Loewer, A.2
Ostheimer, G.J.3
-
11
-
-
2342459790
-
DNA damage-induced apoptosis
-
Norbury C.J., Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004, 23:2797-2808.
-
(2004)
Oncogene
, vol.23
, pp. 2797-2808
-
-
Norbury, C.J.1
Zhivotovsky, B.2
-
12
-
-
67649595826
-
Apoptosis and cancer: The genesis of a research field
-
Cotter T.G. Apoptosis and cancer: The genesis of a research field. Nat Rev Cancer 2009, 9:501-507.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 501-507
-
-
Cotter, T.G.1
-
13
-
-
33646414521
-
ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks
-
Nieborowska-Skorska M., Stoklosa T., Datta M., et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006, 5:994-1000.
-
(2006)
Cell Cycle
, vol.5
, pp. 994-1000
-
-
Nieborowska-Skorska, M.1
Stoklosa, T.2
Datta, M.3
-
14
-
-
34447620928
-
Mechanism of G2/M blockage triggered by activated-Chk1 in regulation of drug-resistance in K562/A02 cell line
-
Wang H.Y., Zhang M., Zou P., et al. Mechanism of G2/M blockage triggered by activated-Chk1 in regulation of drug-resistance in K562/A02 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006, 14:1105-1109.
-
(2006)
Zhongguo Shi Yan Xue Ye Xue Za Zhi
, vol.14
, pp. 1105-1109
-
-
Wang, H.Y.1
Zhang, M.2
Zou, P.3
-
15
-
-
33845317573
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
-
Bao S., Wu Q., McLendon R.E., Hao Y., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
-
(2006)
Nature
, vol.444
, pp. 756-760
-
-
Bao, S.1
Wu, Q.2
McLendon, R.E.3
Hao, Y.4
-
16
-
-
29244437908
-
The role of double-strand break repair: insights from human genetics
-
O'Driscoll M., Jeggo P.A. The role of double-strand break repair: insights from human genetics. Nat Rev Genet 2006, 7:45-54.
-
(2006)
Nat Rev Genet
, vol.7
, pp. 45-54
-
-
O'Driscoll, M.1
Jeggo, P.A.2
-
17
-
-
33646183367
-
DNA damage responses and their many interactions with the replication fork
-
Andreassen P., Ho G., D'Andrea A. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006, 27:883-892.
-
(2006)
Carcinogenesis
, vol.27
, pp. 883-892
-
-
Andreassen, P.1
Ho, G.2
D'Andrea, A.3
-
18
-
-
1542725073
-
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
-
Zhou B.B., Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4:216-225.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 216-225
-
-
Zhou, B.B.1
Bartek, J.2
-
19
-
-
0642286492
-
Drug discovery targeting Chk1 and Chk2 kinases
-
Zhou B.B., Sausville E.A. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 2003, 5:413-421.
-
(2003)
Prog Cell Cycle Res
, vol.5
, pp. 413-421
-
-
Zhou, B.B.1
Sausville, E.A.2
-
20
-
-
0035545996
-
Mammalian G1- and S-phase checkpoints in response to DNA damage
-
Bartek J., Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001, 13:738-747.
-
(2001)
Curr Opin Cell Biol
, vol.13
, pp. 738-747
-
-
Bartek, J.1
Lukas, J.2
-
22
-
-
0012966157
-
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A
-
Sorensen C.S., Syljuasen R.G., Falck J., et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003, 3:247-258.
-
(2003)
Cancer Cell
, vol.3
, pp. 247-258
-
-
Sorensen, C.S.1
Syljuasen, R.G.2
Falck, J.3
-
23
-
-
0034717309
-
Rapid destruction of human Cdc25A in response to DNA damage
-
Mailand N., Falck J., Lukas C., et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288:1425-1429.
-
(2000)
Science
, vol.288
, pp. 1425-1429
-
-
Mailand, N.1
Falck, J.2
Lukas, C.3
-
24
-
-
0036847320
-
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability
-
Mailand N., Podtelejnikov A.V., Groth A., et al. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002, 21:5911-5920.
-
(2002)
EMBO J
, vol.21
, pp. 5911-5920
-
-
Mailand, N.1
Podtelejnikov, A.V.2
Groth, A.3
-
25
-
-
0030611095
-
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216
-
Peng C.Y., Graves P.R., Thoma R.S., et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
-
(1997)
Science
, vol.277
, pp. 1501-1505
-
-
Peng, C.Y.1
Graves, P.R.2
Thoma, R.S.3
-
26
-
-
0032974109
-
Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site
-
Dalal S.N., Schweitzer C.M., Gan J., DeCaprio J.A. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999, 19:4465-4479.
-
(1999)
Mol Cell Biol
, vol.19
, pp. 4465-4479
-
-
Dalal, S.N.1
Schweitzer, C.M.2
Gan, J.3
DeCaprio, J.A.4
-
27
-
-
0033561439
-
Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of Cdc25 nuclear import
-
Yang J., Winkler K., Yoshida M., Kornbluth S. Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of Cdc25 nuclear import. EMBO J 1999, 18:2174-2183.
-
(1999)
EMBO J
, vol.18
, pp. 2174-2183
-
-
Yang, J.1
Winkler, K.2
Yoshida, M.3
Kornbluth, S.4
-
28
-
-
0037415735
-
Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects
-
Zachos G., Rainey M.D., Gillespie D.A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 2003, 22:713-723.
-
(2003)
EMBO J
, vol.22
, pp. 713-723
-
-
Zachos, G.1
Rainey, M.D.2
Gillespie, D.A.3
-
29
-
-
0038013782
-
Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation
-
Gatei M., Sloper K., Soerensen C., et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003, 278:14806-14811.
-
(2003)
J Biol Chem
, vol.278
, pp. 14806-14811
-
-
Gatei, M.1
Sloper, K.2
Soerensen, C.3
-
30
-
-
0037484271
-
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
-
Xiao Z., Chen Z., Gunasekera A.H., et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003, 278:21767-21773.
-
(2003)
J Biol Chem
, vol.278
, pp. 21767-21773
-
-
Xiao, Z.1
Chen, Z.2
Gunasekera, A.H.3
-
31
-
-
0038418869
-
Chk1 and Chk2 kinases in checkpoint control and cancer
-
Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
-
(2003)
Cancer Cell
, vol.3
, pp. 421-429
-
-
Bartek, J.1
Lukas, J.2
-
33
-
-
0035848819
-
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
-
Falck J., Mailand N., Syljuasen R.G., et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842-847.
-
(2001)
Nature
, vol.410
, pp. 842-847
-
-
Falck, J.1
Mailand, N.2
Syljuasen, R.G.3
-
34
-
-
18644375649
-
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
-
Takai H., Naka K., Okada Y., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002, 21:5195-5205.
-
(2002)
EMBO J
, vol.21
, pp. 5195-5205
-
-
Takai, H.1
Naka, K.2
Okada, Y.3
-
35
-
-
34247183037
-
Cross-talk between Chk1 and Chk2 in double-mutant thymocytes
-
Zaugg K., Su Y.-W., Reilly P.T., et al. Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci, USA 2007, 104:3805-3810.
-
(2007)
Proc Natl Acad Sci, USA
, vol.104
, pp. 3805-3810
-
-
Zaugg, K.1
Su, Y.-W.2
Reilly, P.T.3
-
36
-
-
34147206546
-
Specific role of Chk1 phosphorylations in cell survival and checkpoint activation
-
Niida H., Katsuno Y., Banerjee B., Hande M.P., Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 2007, 27:2572-2581.
-
(2007)
Mol Cell Biol
, vol.27
, pp. 2572-2581
-
-
Niida, H.1
Katsuno, Y.2
Banerjee, B.3
Hande, M.P.4
Nakanishi, M.5
-
37
-
-
33748938889
-
The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment
-
Morgan M.A., Parsels L.A., Parsels J.D., Lawrence T.S., Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006, 5:1983-1988.
-
(2006)
Cell Cycle
, vol.5
, pp. 1983-1988
-
-
Morgan, M.A.1
Parsels, L.A.2
Parsels, J.D.3
Lawrence, T.S.4
Maybaum, J.5
-
38
-
-
33748364583
-
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy
-
Xiao Z., Xue S., Sowin T.J., Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006, 5:1935-1943.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 1935-1943
-
-
Xiao, Z.1
Xue, S.2
Sowin, T.J.3
Zhang, H.4
-
39
-
-
37549009033
-
Different S/M checkpoint responses of tumor and non tumor cell lines to DNA replication inhibition
-
Rodriguez-Bravo V., Guaita-Esteruelas S., Salvador N., Bachs O., Agell N. Different S/M checkpoint responses of tumor and non tumor cell lines to DNA replication inhibition. Cancer Research 2007, 67:11648-11656.
-
(2007)
Cancer Research
, vol.67
, pp. 11648-11656
-
-
Rodriguez-Bravo, V.1
Guaita-Esteruelas, S.2
Salvador, N.3
Bachs, O.4
Agell, N.5
-
40
-
-
0034655281
-
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
-
Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000, 60:2108-2112.
-
(2000)
Cancer Res
, vol.60
, pp. 2108-2112
-
-
Busby, E.C.1
Leistritz, D.F.2
Abraham, R.T.3
Karnitz, L.M.4
Sarkaria, J.N.5
-
43
-
-
0033199892
-
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
-
Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999, 59:4375-4382.
-
(1999)
Cancer Res
, vol.59
, pp. 4375-4382
-
-
Sarkaria, J.N.1
Busby, E.C.2
Tibbetts, R.S.3
Roos, P.4
-
44
-
-
0033555260
-
A role for ATR in the DNA damage-induced phosphorylation of p53
-
Tibbetts R.S., Brumbaugh K.M., Williams J.M., et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999, 13:152-157.
-
(1999)
Genes Dev
, vol.13
, pp. 152-157
-
-
Tibbetts, R.S.1
Brumbaugh, K.M.2
Williams, J.M.3
-
45
-
-
0035829685
-
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
-
Koniaras K., Cuddihy A.R., Christopoulos H., Hogg A., O'Connell M.J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001, 20:7453-7463.
-
(2001)
Oncogene
, vol.20
, pp. 7453-7463
-
-
Koniaras, K.1
Cuddihy, A.R.2
Christopoulos, H.3
Hogg, A.4
O'Connell, M.J.5
-
46
-
-
0035062416
-
2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents
-
2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. Anticancer Res 2001, 21:23-28.
-
(2001)
Anticancer Res
, vol.21
, pp. 23-28
-
-
Luo, Y.1
Rockow-Magnone, S.K.2
Joseph, M.K.3
-
47
-
-
0034780430
-
Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism
-
Luo Y., Rockow-Magnone S.K., Kroeger P.E., et al. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia 2001, 3:411-419.
-
(2001)
Neoplasia
, vol.3
, pp. 411-419
-
-
Luo, Y.1
Rockow-Magnone, S.K.2
Kroeger, P.E.3
-
49
-
-
36949012288
-
Targeted Cancer therapies based on the inhibition of DNA strand break repair
-
O'Connor M.J., Martin N.M.B., Smith G.C.M. Targeted Cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007, 26:7816-7824.
-
(2007)
Oncogene
, vol.26
, pp. 7816-7824
-
-
O'Connor, M.J.1
Martin, N.M.B.2
Smith, G.C.M.3
-
50
-
-
0037241328
-
Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators
-
Tenzer A., Pruschy M. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr Med Chem Anticancer Agents 2003, 3:35-46.
-
(2003)
Curr Med Chem Anticancer Agents
, vol.3
, pp. 35-46
-
-
Tenzer, A.1
Pruschy, M.2
-
51
-
-
4444344407
-
G2 checkpoint abrogators as anticancer drugs
-
Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3:513-519.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 513-519
-
-
Kawabe, T.1
-
53
-
-
4444228258
-
Combining DNA damaging agents and checkpoint 1 inhibitors
-
Prudhomme M. Combining DNA damaging agents and checkpoint 1 inhibitors. Curr Med Chem Anticancer Agents 2004, 4:435-438.
-
(2004)
Curr Med Chem Anticancer Agents
, vol.4
, pp. 435-438
-
-
Prudhomme, M.1
-
55
-
-
33745856631
-
Chk1 inhibitors for novel cancer treatment
-
Tao Z.-F., Lin N.-H. Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem 2006, 6:377-388.
-
(2006)
Anticancer Agents Med Chem
, vol.6
, pp. 377-388
-
-
Tao, Z.-F.1
Lin, N.-H.2
-
56
-
-
34447646297
-
Inhibitors of Checkpoint kinases: From discovery to the clinic
-
Janetka J.W., Ashwell S., Zabludoff S., Lyne P. Inhibitors of Checkpoint kinases: From discovery to the clinic. Curr Opin Drug Disc Dev 2007, 10:473-486.
-
(2007)
Curr Opin Drug Disc Dev
, vol.10
, pp. 473-486
-
-
Janetka, J.W.1
Ashwell, S.2
Zabludoff, S.3
Lyne, P.4
-
57
-
-
47149114403
-
Novel inhibitors of checkpoint kinase 1
-
Arrington K.L., Dudkin V.Y. Novel inhibitors of checkpoint kinase 1. Chemmedchem 2007, 2:1571-1585.
-
(2007)
Chemmedchem
, vol.2
, pp. 1571-1585
-
-
Arrington, K.L.1
Dudkin, V.Y.2
-
58
-
-
34247481285
-
Targeting checkpoint kinase 1 in cancer therapeutics
-
Tse A.N., Carvajal R., Schwartz G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007, 13:1955-1960.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1955-1960
-
-
Tse, A.N.1
Carvajal, R.2
Schwartz, G.K.3
-
59
-
-
79651470785
-
Death by releasing the breaks: Chk1 inhibitors as cancer therapeutics
-
Ma C.X., Janetka J.W., Piwnica-Worms H. Death by releasing the breaks: Chk1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17:88-96.
-
(2011)
Trends Mol Med
, vol.17
, pp. 88-96
-
-
Ma, C.X.1
Janetka, J.W.2
Piwnica-Worms, H.3
-
60
-
-
0026616796
-
Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase
-
Parker L.L., Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
-
(1992)
Science
, vol.257
, pp. 1955-1957
-
-
Parker, L.L.1
Piwnica-Worms, H.2
-
61
-
-
0033163714
-
Four-dimensional control of the cell cycle
-
Pines J. Four-dimensional control of the cell cycle. Nat Cell Biol 1999, 1:E73-E79.
-
(1999)
Nat Cell Biol
, vol.1
-
-
Pines, J.1
-
62
-
-
0027244234
-
Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase
-
Heald R., McLoughlin M., McKeon F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993, 74:463-474.
-
(1993)
Cell
, vol.74
, pp. 463-474
-
-
Heald, R.1
McLoughlin, M.2
McKeon, F.3
-
63
-
-
0026006392
-
Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: Evidence for a double block to p34cdc2 kinase activation in vertebrates
-
Krek W., Nigg E.A. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: Evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J 1991, 10:3331-3341.
-
(1991)
EMBO J
, vol.10
, pp. 3331-3341
-
-
Krek, W.1
Nigg, E.A.2
-
64
-
-
0025988705
-
Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates
-
Norbury C., Blow J., Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 1991, 10:3321-3329.
-
(1991)
EMBO J
, vol.10
, pp. 3321-3329
-
-
Norbury, C.1
Blow, J.2
Nurse, P.3
-
65
-
-
0029825066
-
Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells
-
Jin P., Gu Y., Morgan D.O. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996, 134:963-970.
-
(1996)
J Cell Biol
, vol.134
, pp. 963-970
-
-
Jin, P.1
Gu, Y.2
Morgan, D.O.3
-
66
-
-
0032484084
-
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
-
Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
-
(1998)
Science
, vol.282
, pp. 1893-1897
-
-
Matsuoka, S.1
Huang, M.2
Elledge, S.J.3
-
67
-
-
0030867582
-
Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25
-
Sanchez Y., Wong C., Thoma R.S., et al. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277:1497-1501.
-
(1997)
Science
, vol.277
, pp. 1497-1501
-
-
Sanchez, Y.1
Wong, C.2
Thoma, R.S.3
-
68
-
-
0031035528
-
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
-
O'Connell M.J., Raleigh J.M., Verkade H.M., Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997, 16:545-554.
-
(1997)
EMBO J
, vol.16
, pp. 545-554
-
-
O'Connell, M.J.1
Raleigh, J.M.2
Verkade, H.M.3
Nurse, P.4
-
69
-
-
0034125688
-
The G2 DNA damage checkpoint targets both Wee1 and Cdc25
-
Raleigh J.M., O'Connell M.J. The G2 DNA damage checkpoint targets both Wee1 and Cdc25. J Cell Sci 2000, 113:1727-1736.
-
(2000)
J Cell Sci
, vol.113
, pp. 1727-1736
-
-
Raleigh, J.M.1
O'Connell, M.J.2
-
70
-
-
0035158899
-
Positive regulation of Wee1 by Chk1 and 14-3-3 proteins
-
Lee J., Kumagai A., Dunphy W.G. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 2000, 12:551-563.
-
(2000)
Mol Biol Cell
, vol.12
, pp. 551-563
-
-
Lee, J.1
Kumagai, A.2
Dunphy, W.G.3
-
71
-
-
0035890610
-
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator
-
Wang Y., Li J., Booher R.N., et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001, 61:8211-8217.
-
(2001)
Cancer Res
, vol.61
, pp. 8211-8217
-
-
Wang, Y.1
Li, J.2
Booher, R.N.3
-
72
-
-
16544392882
-
Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis
-
Wang Y., Decker S.J., Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004, 3:305-313.
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 305-313
-
-
Wang, Y.1
Decker, S.J.2
Sebolt-Leopold, J.3
-
73
-
-
70949083026
-
Small molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
-
Hirai H., Iwasawa Y., Okada M., et al. Small molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009, 8:2992-3000.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2992-3000
-
-
Hirai, H.1
Iwasawa, Y.2
Okada, M.3
-
74
-
-
3142615903
-
Mechanism by which caffeine potentiates lethality of nitrogen mustard
-
Lau C.C., Pardee A.B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 1982, 79:2942-2946.
-
(1982)
Proc Natl Acad Sci USA
, vol.79
, pp. 2942-2946
-
-
Lau, C.C.1
Pardee, A.B.2
-
75
-
-
0020367120
-
Abolition by cycloheximide of caffeine-enhanced lethality of alkylating agents in hamster cells
-
Das S.K., Lau C.C., Pardee A.B. Abolition by cycloheximide of caffeine-enhanced lethality of alkylating agents in hamster cells. Cancer Res 1982, 42:4499-4504.
-
(1982)
Cancer Res
, vol.42
, pp. 4499-4504
-
-
Das, S.K.1
Lau, C.C.2
Pardee, A.B.3
-
76
-
-
0025282246
-
Override of the radiation-induced mitotic block in human tumor cells by methylxanthines and its relationship to the potentiation of cytotoxicity
-
Musk S.R., Steel G.G. Override of the radiation-induced mitotic block in human tumor cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int J Radiat Biol 1990, 57:1105-1112.
-
(1990)
Int J Radiat Biol
, vol.57
, pp. 1105-1112
-
-
Musk, S.R.1
Steel, G.G.2
-
77
-
-
0025838748
-
Efficacy of pentoxyfylline as a modulator of alkylating agent activity in vitro and in vivo
-
Teicher B.A., Holden S.A., Herman T.S., Epelbaum R., Pardee A.B., Dezube B. Efficacy of pentoxyfylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 1991, 11:1555-1560.
-
(1991)
Anticancer Res
, vol.11
, pp. 1555-1560
-
-
Teicher, B.A.1
Holden, S.A.2
Herman, T.S.3
Epelbaum, R.4
Pardee, A.B.5
Dezube, B.6
-
78
-
-
0032903795
-
Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines
-
Ribeiro J.C., Barnetson A.R., Jackson P., Ow K., Links M., Russell P.J. Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines. Int J Radiat Biol 1999, 75:481-492.
-
(1999)
Int J Radiat Biol
, vol.75
, pp. 481-492
-
-
Ribeiro, J.C.1
Barnetson, A.R.2
Jackson, P.3
Ow, K.4
Links, M.5
Russell, P.J.6
-
79
-
-
0034088343
-
Mechanism of caffeine-induced checkpoint override in fission yeast
-
Moser B.A., Brondello J.-M., Baber-Furnari B., Russell P. Mechanism of caffeine-induced checkpoint override in fission yeast. Mol Cell Biol 2000, 20:4288-4294.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 4288-4294
-
-
Moser, B.A.1
Brondello, J.-M.2
Baber-Furnari, B.3
Russell, P.4
-
80
-
-
0035393498
-
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells
-
Dai Y., Yu C., Singh V., et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001, 61:5106-5115.
-
(2001)
Cancer Res
, vol.61
, pp. 5106-5115
-
-
Dai, Y.1
Yu, C.2
Singh, V.3
-
81
-
-
0029871688
-
UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
-
Kawakami K., Futami H., Takahara J., Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996, 219:778-783.
-
(1996)
Biochem Biophys Res Commun
, vol.219
, pp. 778-783
-
-
Kawakami, K.1
Futami, H.2
Takahara, J.3
Yamaguchi, K.4
-
82
-
-
0034040974
-
UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century
-
Akinaga S., Sugiyama K., Akiyama T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century. Anticancer Drug Des 2000, 15:43-52.
-
(2000)
Anticancer Drug Des
, vol.15
, pp. 43-52
-
-
Akinaga, S.1
Sugiyama, K.2
Akiyama, T.3
-
83
-
-
0026425587
-
Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
-
Akinaga S., Gomi K., Morimoto M., Tamaoki T., Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991, 51:4888-4892.
-
(1991)
Cancer Res
, vol.51
, pp. 4888-4892
-
-
Akinaga, S.1
Gomi, K.2
Morimoto, M.3
Tamaoki, T.4
Okabe, M.5
-
84
-
-
19944432818
-
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-xL protein
-
Bhonde M.R., Hanski M.-L., Magrini R. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-xL protein. Oncogene 2005, 24:148-156.
-
(2005)
Oncogene
, vol.24
, pp. 148-156
-
-
Bhonde, M.R.1
Hanski, M.-L.2
Magrini, R.3
-
85
-
-
0033913696
-
Inhibition of CDKs as a therapeutic modality
-
Sausville E.A., Johnson J., Alley M., et al. Inhibition of CDKs as a therapeutic modality. Ann NY Acad Sci 2000, 910:207-221.
-
(2000)
Ann NY Acad Sci
, vol.910
, pp. 207-221
-
-
Sausville, E.A.1
Johnson, J.2
Alley, M.3
-
86
-
-
0029992520
-
Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor
-
Bunch R.T., Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor. Clin Cancer Res 1996, 2:791-797.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 791-797
-
-
Bunch, R.T.1
Eastman, A.2
-
87
-
-
0033953099
-
UCN-01 Selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
-
Sugiyama K., Shimizu M., Akiyama T., et al. UCN-01 Selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 2000, 85:703-709.
-
(2000)
Int J Cancer
, vol.85
, pp. 703-709
-
-
Sugiyama, K.1
Shimizu, M.2
Akiyama, T.3
-
88
-
-
31544452150
-
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: A Princess Margaret hospital phase II consortium study
-
Hotte S.J., Oza A., Winquist E.W., et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: A Princess Margaret hospital phase II consortium study. Ann Oncol 2006, 17:334-340.
-
(2006)
Ann Oncol
, vol.17
, pp. 334-340
-
-
Hotte, S.J.1
Oza, A.2
Winquist, E.W.3
-
89
-
-
33746388284
-
Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
-
Perez R.P., Lewis L.D., Beelen A.P., et al. Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006, 12:7079-7085.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7079-7085
-
-
Perez, R.P.1
Lewis, L.D.2
Beelen, A.P.3
-
90
-
-
33644755493
-
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
-
Sampath D., Cortes J., Estrov Z., et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006, 107:2517-2524.
-
(2006)
Blood
, vol.107
, pp. 2517-2524
-
-
Sampath, D.1
Cortes, J.2
Estrov, Z.3
-
91
-
-
0346452207
-
The cyclin-dependent kinase (CDK) Inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium Phase I Trial
-
Abst 987
-
Gandara D.R., Lara P.N., Longmate J., et al. The cyclin-dependent kinase (CDK) Inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium Phase I Trial. Proc Am Soc Clin Oncol (ASCO) 2003, 22. Abst 987.
-
(2003)
Proc Am Soc Clin Oncol (ASCO)
, vol.22
-
-
Gandara, D.R.1
Lara, P.N.2
Longmate, J.3
-
92
-
-
71349083859
-
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
-
Kummar S., Guiterrez M.E., Gardener E.R., et al. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 2010, 65:383-389.
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 383-389
-
-
Kummar, S.1
Guiterrez, M.E.2
Gardener, E.R.3
-
93
-
-
33846567414
-
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo
-
Mathews D.J., Yakes F.M., Chen J., et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007, 6:104-110.
-
(2007)
Cell Cycle
, vol.6
, pp. 104-110
-
-
Mathews, D.J.1
Yakes, F.M.2
Chen, J.3
-
94
-
-
34447628254
-
Inhibition of CHKs in a leukemia model abrogates DNA damage checkpoints and promotes mitotic catastrophe
-
Abst 5385
-
Clary D.O. Inhibition of CHKs in a leukemia model abrogates DNA damage checkpoints and promotes mitotic catastrophe. Proc Am Assoc Cancer Res 2007, 48. Abst 5385.
-
(2007)
Proc Am Assoc Cancer Res
, vol.48
-
-
Clary, D.O.1
-
95
-
-
2342635919
-
Cell death by mitotic catastrophe: a molecular definition
-
Castedo M., Perfettinin J.-L., Roumier T., et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
-
(2004)
Oncogene
, vol.23
, pp. 2825-2837
-
-
Castedo, M.1
Perfettinin, J.-L.2
Roumier, T.3
-
96
-
-
38949195786
-
Dissecting the roles of Chk1 and Chk2 in mitotic catastrophe using chemical genetics
-
Abst 344
-
Matthews D.J. Dissecting the roles of Chk1 and Chk2 in mitotic catastrophe using chemical genetics. Eur J Cancer 2006, 4. Abst 344.
-
(2006)
Eur J Cancer
, vol.4
-
-
Matthews, D.J.1
-
97
-
-
84882409088
-
Phase 1 study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in subjects with advanced malignancies
-
Abst 395
-
Tse A.N., Yazji S., Naing A., et al. Phase 1 study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in subjects with advanced malignancies. Eur J Cancer Suppl 2008, 6. Abst 395.
-
(2008)
Eur J Cancer Suppl
, vol.6
-
-
Tse, A.N.1
Yazji, S.2
Naing, A.3
-
98
-
-
1842450527
-
Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening
-
Lyne P.D., Kenny P.W., Cosgrove D.A., et al. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J Med Chem 2004, 47:1962-1968.
-
(2004)
J Med Chem
, vol.47
, pp. 1962-1968
-
-
Lyne, P.D.1
Kenny, P.W.2
Cosgrove, D.A.3
-
99
-
-
84882311402
-
Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases
-
Abst A232
-
Ashwell S., Caleb B., Deng C., et al. Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases. Mol Cancer Ther 2007, 6. Abst A232.
-
(2007)
Mol Cancer Ther
, vol.6
-
-
Ashwell, S.1
Caleb, B.2
Deng, C.3
-
100
-
-
84882342148
-
Structure activity and structure property relationships of a novel series of potent inhibitors of Checkpoint kinases
-
Abst A233
-
Almeida L., Ashwell S., Ayres D., et al. Structure activity and structure property relationships of a novel series of potent inhibitors of Checkpoint kinases. Mol Cancer Ther 2007, 6. Abst A233.
-
(2007)
Mol Cancer Ther
, vol.6
-
-
Almeida, L.1
Ashwell, S.2
Ayres, D.3
-
101
-
-
52949139387
-
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
-
Zabludoff S., Deng C., Grondine M., et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008, 7:2955-2966.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2955-2966
-
-
Zabludoff, S.1
Deng, C.2
Grondine, M.3
-
102
-
-
47149091445
-
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors
-
Janetka J., Almeida L., Ashwell S., et al. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorg Med Chem Letts 2008, 18:4242-4248.
-
(2008)
Bioorg Med Chem Letts
, vol.18
, pp. 4242-4248
-
-
Janetka, J.1
Almeida, L.2
Ashwell, S.3
-
103
-
-
77950650401
-
In vitro and in vivo radiosensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
-
Mitchell J.B., Choudhuri R., Fabre K., et al. In vitro and in vivo radiosensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16:2076-2084.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2076-2084
-
-
Mitchell, J.B.1
Choudhuri, R.2
Fabre, K.3
-
104
-
-
77953770987
-
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
-
Morgan M.A., Parsels L.A., Zhao L., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010, 70:4972-4991.
-
(2010)
Cancer Res
, vol.70
, pp. 4972-4991
-
-
Morgan, M.A.1
Parsels, L.A.2
Zhao, L.3
-
105
-
-
1642471800
-
Mechanisms of apoptosis induction by nucleoside analogs
-
Sampath D., Rao V.A., Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003, 22:9063-9074.
-
(2003)
Oncogene
, vol.22
, pp. 9063-9074
-
-
Sampath, D.1
Rao, V.A.2
Plunkett, W.3
-
106
-
-
33645825609
-
Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase
-
Petermann E., Maya-Mendoza A., Zachos G., et al. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006, 26:3319-3326.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 3319-3326
-
-
Petermann, E.1
Maya-Mendoza, A.2
Zachos, G.3
-
107
-
-
27844561114
-
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival
-
Karnitz L.M., Flatten K.S., Wagner J.M., et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005, 68:1636-1644.
-
(2005)
Mol Pharmacol
, vol.68
, pp. 1636-1644
-
-
Karnitz, L.M.1
Flatten, K.S.2
Wagner, J.M.3
-
108
-
-
17144377827
-
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons
-
Flatten K., Dai N.T., Vroman B.T., et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005, 280:14349-14355.
-
(2005)
J Biol Chem
, vol.280
, pp. 14349-14355
-
-
Flatten, K.1
Dai, N.T.2
Vroman, B.T.3
-
109
-
-
34447625126
-
A novel inhibitor of the protein kinase Chk1: Studies on the mechanism of action
-
Abst 4416
-
Blasina A., Kornmann J.F., Chen E., et al. A novel inhibitor of the protein kinase Chk1: Studies on the mechanism of action. Proc Am Assoc Cancer Res 2005, 46. Abst 4416.
-
(2005)
Proc Am Assoc Cancer Res
, vol.46
-
-
Blasina, A.1
Kornmann, J.F.2
Chen, E.3
-
110
-
-
33745816633
-
Small molecule Chk1 inhibitor potentiates antitumour activity of chemotherapeutic agents in vivo
-
Abst 4417
-
Anderes K.L., Blasina A., Castillo R., et al. Small molecule Chk1 inhibitor potentiates antitumour activity of chemotherapeutic agents in vivo. Proc Am. Assoc Cancer Res 2005, 46. Abst 4417.
-
(2005)
Proc Am. Assoc Cancer Res
, vol.46
-
-
Anderes, K.L.1
Blasina, A.2
Castillo, R.3
-
111
-
-
84882427713
-
Imaging with FLT-PET demonstrates that PF00477736, an inhibitor of Chk1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts
-
Abst 3045
-
McArthur G.A. Imaging with FLT-PET demonstrates that PF00477736, an inhibitor of Chk1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts. Proc Am Soc Clin Oncol 2006, 25. Abst 3045.
-
(2006)
Proc Am Soc Clin Oncol
, vol.25
-
-
McArthur, G.A.1
-
112
-
-
84882322669
-
Characterization of a novel and selective inhibitor of checkpoint kinase 1: Breaching the tumour's last checkpoint defense against chemotherapeutic agents
-
Blasina A., Kornmann J.F., Chen E., et al. Characterization of a novel and selective inhibitor of checkpoint kinase 1: Breaching the tumour's last checkpoint defense against chemotherapeutic agents. Eur J Cancer Suppl 2006, 4:115.
-
(2006)
Eur J Cancer Suppl
, vol.4
, pp. 115
-
-
Blasina, A.1
Kornmann, J.F.2
Chen, E.3
-
113
-
-
34447638042
-
PF00477736 an inhibitor of Chk1 enhances the antitumour activity of docetaxel indicating a role for Chk1 in the mitotic spindle checkpoint
-
Abst 4373
-
Hallin M., Zhang C., Yan Z., et al. PF00477736 an inhibitor of Chk1 enhances the antitumour activity of docetaxel indicating a role for Chk1 in the mitotic spindle checkpoint. Proc Am Assoc Cancer Res 2007, 48. Abst 4373.
-
(2007)
Proc Am Assoc Cancer Res
, vol.48
-
-
Hallin, M.1
Zhang, C.2
Yan, Z.3
-
115
-
-
33947517675
-
Mechanisms of radiation enhancement by the Chk1 inhibitor PF00477736
-
Li G., Elder R.T., Qin K., et al. Mechanisms of radiation enhancement by the Chk1 inhibitor PF00477736. J Biol Chem 2007, 282:7287-7298.
-
(2007)
J Biol Chem
, vol.282
, pp. 7287-7298
-
-
Li, G.1
Elder, R.T.2
Qin, K.3
-
116
-
-
79958804691
-
Phase I clinical trial of gemcitabine (GEM) in combination with PF00477736 (PF-736), a selective inhibitor of Chk1 kinase
-
Abst 3062
-
Brega N., McArthur G.A., Britten C., et al. Phase I clinical trial of gemcitabine (GEM) in combination with PF00477736 (PF-736), a selective inhibitor of Chk1 kinase. J Clin Oncol 2010, 28. Abst 3062.
-
(2010)
J Clin Oncol
, vol.28
-
-
Brega, N.1
McArthur, G.A.2
Britten, C.3
-
117
-
-
84882358250
-
Discovery of pyrazinyl ureas as inhibitors of the cell-cycle checkpoint kinase Chk1
-
Presented at 228th ACS National Meeting, Philadelphia, USA, 22-26 August
-
Kesicki EA, Gaudino JJ, Cook AW, et al. Discovery of pyrazinyl ureas as inhibitors of the cell-cycle checkpoint kinase Chk1. Presented at 228th ACS National Meeting, Philadelphia, USA, 22-26 August 2004.
-
(2004)
-
-
Kesicki, E.A.1
Gaudino, J.J.2
Cook, A.W.3
-
118
-
-
84882351680
-
-
Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics," Berlin, Germany, 16-19 November
-
Marshall M, King C, Barnard H, et al. Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics," Berlin, Germany, 16-19 November 2010.
-
(2010)
-
-
Marshall, M.1
King, C.2
Barnard, H.3
-
119
-
-
84882334052
-
-
Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," Berlin, Germany, 16-19 November
-
Marshall M, Barnard D, Diaz H, et al. Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," Berlin, Germany, 16-19 November 2010.
-
(2010)
-
-
Marshall, M.1
Barnard, D.2
Diaz, H.3
-
120
-
-
84882350076
-
-
A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," Berlin, Germany, 16-19 November
-
Weiss G, Donehower E, Westin A, et al. A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. Presented at 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," Berlin, Germany, 16-19 November 2010.
-
(2010)
-
-
Weiss, G.1
Donehower, E.2
Westin, A.3
-
121
-
-
79651472860
-
Targeting the replication checkpoint with a potent and selective Chk1 inhibitor
-
Presented at 2009 AACR Annual Meeting, Denver, USA, 18-22April
-
Parry DA. Targeting the replication checkpoint with a potent and selective Chk1 inhibitor. Presented at 2009 AACR Annual Meeting, Denver, USA, 18-22April 2009.
-
(2009)
-
-
Parry, D.A.1
-
122
-
-
84882426654
-
-
Efficacy of the Chk1 inhibitor SCH-900776 at abrogating cell cycle arrest and enhancing DNA damage-induced cytotoxicity: comparison with UCN-01. Presented at 2010 AACR Annual Meeting, Washington, DC, USA, 17-21 April
-
Eastman A, Montano RE, Garner KM, et al. Efficacy of the Chk1 inhibitor SCH-900776 at abrogating cell cycle arrest and enhancing DNA damage-induced cytotoxicity: comparison with UCN-01. Presented at 2010 AACR Annual Meeting, Washington, DC, USA, 17-21 April 2010.
-
(2010)
-
-
Eastman, A.1
Montano, R.E.2
Garner, K.M.3
-
123
-
-
79651475663
-
Phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (Chk1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors
-
Abst 3064
-
Daud A.A. phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (Chk1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010, 15s. Abst 3064.
-
(2010)
J Clin Oncol
, vol.15 s
-
-
Daud, A.A.1
-
124
-
-
0028783413
-
Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15
-
Mueller P.R., Coleman T.R., Kumagai A., Dunphy W.G. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995, 270:86-90.
-
(1995)
Science
, vol.270
, pp. 86-90
-
-
Mueller, P.R.1
Coleman, T.R.2
Kumagai, A.3
Dunphy, W.G.4
-
125
-
-
84882380343
-
Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy
-
Abst 10596
-
Mason K., Pickett C., Ware H., et al. Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy. J Clin Oncol 2010, 15s. Abst 10596.
-
(2010)
J Clin Oncol
, vol.15 s
-
-
Mason, K.1
Pickett, C.2
Ware, H.3
-
126
-
-
79956224870
-
Phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors
-
Abst 3067
-
Leijen S., Schellens J.H., Shapiro G., et al. Phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010, 15s. Abst 3067.
-
(2010)
J Clin Oncol
, vol.15 s
-
-
Leijen, S.1
Schellens, J.H.2
Shapiro, G.3
-
127
-
-
0033566082
-
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
-
Chaturvedi P., Eng W.K., Zhu Y., et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18:4047-4054.
-
(1999)
Oncogene
, vol.18
, pp. 4047-4054
-
-
Chaturvedi, P.1
Eng, W.K.2
Zhu, Y.3
-
128
-
-
9244251125
-
Cell cycle checkpoints and cancer
-
Kastan M.B., Bartek J. Cell cycle checkpoints and cancer. Nature 2004, 432:316-323.
-
(2004)
Nature
, vol.432
, pp. 316-323
-
-
Kastan, M.B.1
Bartek, J.2
-
129
-
-
38949133032
-
Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase
-
Rainey M.D., Black E.J., Zachos G., Gillespie D.A. Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase. Oncogene 2008, 27:896-906.
-
(2008)
Oncogene
, vol.27
, pp. 896-906
-
-
Rainey, M.D.1
Black, E.J.2
Zachos, G.3
Gillespie, D.A.4
-
130
-
-
34147177714
-
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2
-
Carlessi L., Buscemi G., Larson G., et al. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007, 6:935-944.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 935-944
-
-
Carlessi, L.1
Buscemi, G.2
Larson, G.3
-
131
-
-
0036724625
-
Chk2 is a tumor suppressor that regulates apoptosis in both an ATM-dependent and ATM independent manner
-
Hirao A., Cheung A., Cuncan G., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ATM-dependent and ATM independent manner. Mol Cell Biol 2002, 22:6521-6532.
-
(2002)
Mol Cell Biol
, vol.22
, pp. 6521-6532
-
-
Hirao, A.1
Cheung, A.2
Cuncan, G.3
-
132
-
-
0037162506
-
Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response
-
Jack M.T., Woo R.A., Hirao A., et al. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002, 99:9825-9829.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 9825-9829
-
-
Jack, M.T.1
Woo, R.A.2
Hirao, A.3
-
133
-
-
0034629072
-
DNA damage-induced activation of p53 by the checkpoint kinase Chk2
-
Hirao A., Kong Y.Y., Matsuoka S., et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000, 287:1824-1827.
-
(2000)
Science
, vol.287
, pp. 1824-1827
-
-
Hirao, A.1
Kong, Y.Y.2
Matsuoka, S.3
-
134
-
-
0030706078
-
UCN-01 in ovary cancer cells; effective as a single agent and in combination with cis-diaminedichloroplatinum(II) independent of p53 status
-
in A
-
in A, Yan X.J., Rosales N., et al. UCN-01 in ovary cancer cells; effective as a single agent and in combination with cis-diaminedichloroplatinum(II) independent of p53 status. Clin Cancer Res 1997, 3:2087-2097. in A.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 2087-2097
-
-
in, A.1
Yan, X.J.2
Rosales, N.3
-
135
-
-
0035422203
-
Abrogation of the Chk1-mediated (G2) checkpoint pathway potentiates temozolominde-induced toxicity in a p53-independent manner in human glioblastoma cells
-
Hirose Y., Berger M.S., Pieper R.O. Abrogation of the Chk1-mediated (G2) checkpoint pathway potentiates temozolominde-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001, 61:5843-5849.
-
(2001)
Cancer Res
, vol.61
, pp. 5843-5849
-
-
Hirose, Y.1
Berger, M.S.2
Pieper, R.O.3
-
136
-
-
4644318231
-
Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint kinase inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe
-
Tse A.N., Schwarz G.K. Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint kinase inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 2004, 64:6635-6644.
-
(2004)
Cancer Res
, vol.64
, pp. 6635-6644
-
-
Tse, A.N.1
Schwarz, G.K.2
-
137
-
-
0037093087
-
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray
-
Han H., Bearss D.J., Browne L.W., et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002, 62:2890-2896.
-
(2002)
Cancer Res
, vol.62
, pp. 2890-2896
-
-
Han, H.1
Bearss, D.J.2
Browne, L.W.3
-
138
-
-
0032526320
-
Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation
-
Vispe S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998, 26:2859-2864.
-
(1998)
Nucleic Acids Res
, vol.26
, pp. 2859-2864
-
-
Vispe, S.1
Cazaux, C.2
Lesca, C.3
Defais, M.4
-
140
-
-
0034713347
-
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma
-
Maacke H., Jost K., Opitz S., et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000, 19:2791-2795.
-
(2000)
Oncogene
, vol.19
, pp. 2791-2795
-
-
Maacke, H.1
Jost, K.2
Opitz, S.3
-
141
-
-
84882447390
-
-
Olaparib (AZD2281; PARP inhibitor) and AZD7762 (CHK inhibitor) act synergistically to enhance cell death and reduce tumor growth in preclinical models. Presented at 2009 AACR Annual Meeting, Denver, USA, 18-22 April 2009, Abst 2487.
-
Zabludoff SD, Zhu AC, Deng C, et al. Olaparib (AZD2281; PARP inhibitor) and AZD7762 (CHK inhibitor) act synergistically to enhance cell death and reduce tumor growth in preclinical models. Presented at 2009 AACR Annual Meeting, Denver, USA, 18-22 April 2009, Abst 2487.
-
-
-
Zabludoff, S.D.1
Zhu, A.C.2
Deng, C.3
-
142
-
-
0034967556
-
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
-
Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001, 21:4129-4139.
-
(2001)
Mol Cell Biol
, vol.21
, pp. 4129-4139
-
-
Zhao, H.1
Piwnica-Worms, H.2
-
143
-
-
77950961695
-
Gamma;H2AX: a sensitive molecular marker of DNA damage and repair
-
Mah L.J., El-Osta A., Karagiannis T.C. gamma;H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010, 24:679-686.
-
(2010)
Leukemia
, vol.24
, pp. 679-686
-
-
Mah, L.J.1
El-Osta, A.2
Karagiannis, T.C.3
-
144
-
-
70450224676
-
H2AX: functional roles and potential applications
-
Dickey J.S., Redon C.E., Nakamura A.J., et al. H2AX: functional roles and potential applications. Chromosoma 2009, 118:683-692.
-
(2009)
Chromosoma
, vol.118
, pp. 683-692
-
-
Dickey, J.S.1
Redon, C.E.2
Nakamura, A.J.3
-
146
-
-
0032861343
-
Megabase chromatin domains involved in DNA double-strand breaks in vivo
-
Rogakou E.P., Boon C., Redon C., Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999, 146:905-916.
-
(1999)
J Cell Biol
, vol.146
, pp. 905-916
-
-
Rogakou, E.P.1
Boon, C.2
Redon, C.3
Bonner, W.M.4
-
147
-
-
0036789173
-
Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody
-
Sedelnikova O.A., Rogakou E.P., Panyutin I.G., Bonner W.M. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 2002, 158:486-492.
-
(2002)
Radiat Res
, vol.158
, pp. 486-492
-
-
Sedelnikova, O.A.1
Rogakou, E.P.2
Panyutin, I.G.3
Bonner, W.M.4
-
148
-
-
44449136965
-
HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response
-
Ayoub N., Jeyasekharan A.D., Bernal J.A., Venkitaraman A.R. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008, 453:682-686.
-
(2008)
Nature
, vol.453
, pp. 682-686
-
-
Ayoub, N.1
Jeyasekharan, A.D.2
Bernal, J.A.3
Venkitaraman, A.R.4
-
149
-
-
10844237358
-
Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation
-
Syljuasen R.G., Sorensen C.S., Nylandsted J., et al. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res 2004, 64:9035-9040.
-
(2004)
Cancer Res
, vol.64
, pp. 9035-9040
-
-
Syljuasen, R.G.1
Sorensen, C.S.2
Nylandsted, J.3
-
150
-
-
77949698506
-
Strategies towards more effective anticancer therapies: targeting DNA damage response pathways
-
Ashwell S. Strategies towards more effective anticancer therapies: targeting DNA damage response pathways. Expert Rev Clin Pharmacol 2010, 3:103-115.
-
(2010)
Expert Rev Clin Pharmacol
, vol.3
, pp. 103-115
-
-
Ashwell, S.1
-
151
-
-
33749626550
-
Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit
-
Leung-Pineda V., Ryan C.E., Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006, 26:7529-7538.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 7529-7538
-
-
Leung-Pineda, V.1
Ryan, C.E.2
Piwnica-Worms, H.3
-
152
-
-
77953711939
-
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
-
Hirai H., Arai T., Okada M., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010, 9:514-522.
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 514-522
-
-
Hirai, H.1
Arai, T.2
Okada, M.3
-
153
-
-
67649710471
-
Discovery of gene expression based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor
-
Mizuarai S., Yamanaka K., Itadani H., et al. Discovery of gene expression based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009, 8:34-45.
-
(2009)
Mol Cancer
, vol.8
, pp. 34-45
-
-
Mizuarai, S.1
Yamanaka, K.2
Itadani, H.3
-
154
-
-
34250010317
-
Chk1 regulates the density of active replication origins during the vertebrate S phase
-
Maya-Mendoza A., Petermann E., Gillespie D.A., Caldecott K.W., Jackson D.A. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 2007, 26:2719-2731.
-
(2007)
EMBO J
, vol.26
, pp. 2719-2731
-
-
Maya-Mendoza, A.1
Petermann, E.2
Gillespie, D.A.3
Caldecott, K.W.4
Jackson, D.A.5
-
155
-
-
68249126215
-
Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
-
Stracker T.H., Usui T., Petrini J.H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 2009, 8:1047-1054.
-
(2009)
DNA Repair (Amst)
, vol.8
, pp. 1047-1054
-
-
Stracker, T.H.1
Usui, T.2
Petrini, J.H.3
|